Vutrisiran : Alnylam Pharmaceuticals reveals positive results from HELIOS-B Phase 3 study

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, has unveiled promising results from the HELIOS-B Phase 3 study of vutrisiran, a ... Read More